Wound Healing Peptide

Background

Poor wound healing after trauma, surgery, acute illness, or chronic disease conditions affects millions of people worldwide each year.

In particular, foot ulcers are a common complication of poorly controlled diabetes. Diabetic foot ulcers (DFUs) respond poorly to treatment and often require limb amputation as a life-saving procedure, adding clinical and psychological consequences of limb loss to morbidity caused by ulcers.

Despite a large variety of wound care products, only 3 products have been approved by the Food and Drug Administration (FDA) for the treatment of diabetic foot ulcers. Of these, 2 are bioengineered skin-cares products, and the third is a growth-factor whose healing rates are 36-50% after 20 weeks. It is critical to develop a better wound dressing material that can promote local tissue regeneration.

The underlying discovery came from study of Opisthorchiasis, which is a tropical disease caused by ingestion of the food-borne parasite Opisthorchis viverrini (also known as the Southeast Asian liver fluke). JCU researchers found the parasite secretes a peptide, named Ov-GRN-1, to repair damage it causes in bile ducts from feeding. Ov-GRN-1 belongs to a secreted growth factor family found in a majority of organisms. Granulin-like proteins are heavily involved in wound healing. The original protein has complex knotted protein structure. JCU researchers generated sets of synthesised peptides derived from Ov‑GRN-1 and screened them for increased stability, improved production yield, and enhanced activity in vitro and in vivo. Of these, JCU303, a minimal 24-mer peptide was found to have superior wound healing properties, more stability and reduced immunogenic potential compared to the parent protein.

Figure 1.

  • Efficacy: 20% faster healing than nearest competitor in animal studies
  • Safety: May offer safety advantages
  • Indication: Potentially broader indications
  • Cost: Peptide manufacturing easier & less expensive than biologics
  • Activity
    • Stimulates fibroblast migration & proliferation, collagen production
    • Accelerates wound re-epithelialisation
    • Restores depleted growth factor activity
    • Promotes re-vascularisation

Topical treatment of:

  • Chronic wounds
    • Diabetic foot ulcer
    • Pressure Ulcers
    • Venous Stasis Ulcers
  • Burns
  • Surgical wounds

We are seeking partners for continued development of the lead candidate through preclinical development & clinical trials.

Seeking:

  • Development partners
  • Commercial partner
  • Licensing
  • University spin out
  • Seeking investment

IP Status

  • Patent application submitted

Patent

  • PCT/AU2017/050959

Contact details

Photo of Pradeep Sadasivan Pillai

Pradeep Sadasivan Pillai

Associate, Development and Commercialisation

pradeep.sadasivanpillai@jcu.edu.au